Benzalkonium chloride + polyhexanide is under clinical development by Turn Therapeutics and currently in Phase I for Onychomycosis (Tinea Unguium). According to GlobalData, Phase I drugs for Onychomycosis (Tinea Unguium) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Benzalkonium chloride + polyhexanide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Benzalkonium chloride + polyhexanide overview

Benzalkonium chloride and Polihexanide (GX-03/0.5 percent PHMB, Polyhexamethylene biguanide) is under development for the treatment of topical skin infections, onychomycosis, dermatitis (eczema), basal cell carcinoma and. The drug candidate is administered by topical route for onychomycosis and through intranasal route for Covid-19 and is being developed based on PermaFusion technology platform.
It was also under development for Coronavirus disease 2019 (COVID-19).

Turn Therapeutics overview

Turn Therapeutics, Inc., a pharmaceutical and medical device company that provides wound care, dermatology, skin diseases, and other services. The company is headquartered in United States.

For a complete picture of Benzalkonium chloride + polyhexanide’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.